San Diego's Curebound Cancer Challenge Returns as Grant Applications Surge 21%, Signaling Urgent Need for Early-Stage Cancer Research Funding
Key Insights
Curebound (search) Cancer Challenge returns August 1, 2026, at UC San Diego, having raised $24.5 million since launch with 100% of participant-raised dollars funding collaborative cancer research.
Grant applications surged 21% year-over-year to a record 186 letters of intent from 69 teams, reflecting an extraordinary pipeline of innovative cancer research awaiting funding.
A 2024 Discovery Grant of $250,000 to Dr. Hojun Li for pediatric leukemia (search) prevention research helped secure nearly $8.6 million in follow-on funding, a 34-fold return.
On Saturday, August 1, 2026, San Diego will host the Curebound (search) Cancer Challenge at UC San Diego, the county's largest community-driven fundraiser for cancer research. Formerly known as Padres Pedal the Cause, the event has united more than 20,000 participants and raised $24.5 million since its inception, with 100% of every participant-raised dollar directly funding collaborative research across the region's leading institutions.
This year's event arrives at a moment of unprecedented demand. Curebound (search) has received 186 letters of intent from 69 teams seeking cancer study grants — a 21% increase from the prior year and an all-time record. "That surge represents an extraordinary pipeline of innovative cancer research happening in San Diego and waiting to be funded," Curebound stated. "Funds raised at the Challenge help determine how much of that pipeline Curebound can fulfill."
A Model of Catalytic Research Investment
Curebound (search)'s funding model targets early-stage, high-risk research with what the organization describes as a powerful compounding effect: seed funding for Discovery grants that develop early science, often unlocking major follow-on investment.
A striking illustration is the 2024 Discovery Grant awarded to Dr. Hojun Li of UC San Diego and Rady Children's Health, supporting research into pediatric leukemia (search) prevention. Curebound (search)'s initial $250,000 investment helped Dr. Li secure nearly $8.6 million in additional funding to advance safer, less toxic bone marrow transplant strategies for children with leukemia — representing a 34-fold return on the original grant.
"This is what early investment in science can do," said Curebound (search) CEO Robin Toft. "A single grant, placed at exactly the right moment, can be the difference between a brilliant idea stalling out and a breakthrough reaching the children who need it. That's the multiplier effect of giving to Curebound: every dollar is designed to attract many more, so that the boldest, highest-risk research gets the chance to become tomorrow's cure. When you invest in us, you're investing in survivorship."
San Diego's Collaborative Cancer Research Ecosystem
San Diego has emerged as a leading cancer research hub, anchored by three NCI-Designated Cancer Centers, all Curebound (search) partner institutions. UC San Diego Moores Cancer Center (search), the region's only NCI-Designated Comprehensive Cancer Center (designated in 1978, comprehensive in 2001), provides comprehensive clinical care, patient trials, and research, with cancer services ranked number one in San Diego for 2025-2026.
The Salk Institute for Biological Studies (search) has held NCI-designated Basic Laboratory Cancer Center status since 1973, making it one of only seven such centers in the United States focused on foundational research. Sanford Burnham Prebys Medical Discovery Institute (search), an NCI-designated Basic Laboratory Cancer Center since 1981, focuses on laboratory research and drug discovery, earning a merit extension in 2025 for its cancer center program.
Curebound (search)-funded research also extends to the La Jolla Institute for Immunology, Rady Children's Health, and Scripps Research Institute, forming what Toft described as "a uniquely collaborative ecosystem."
A Community United for Survivorship
The Curebound (search) Cancer Challenge offers participants multiple ways to engage, including three bike routes, 5K and 10K runs, spin classes, and — new this year — yoga sessions, all set along the scenic Torrey Pines coastline. The family-friendly event features a Kid Zone, live music, local craft beer from Coronado Brewing Company and JuneShine, and a premium food experience provided by UC San Diego.
The Honor Wall, presented by Janux Therapeutics, and the Survivor Bell provide spaces for the community to honor loved ones and celebrate survivors. This year's event carries particular resonance following the recent passing of Joe Pangelinan, a cancer fighter and longtime Curebound (search) spokesperson, after a five-year battle with lung cancer (search). His widow, Cindy Pangelinan, reflected on his legacy: "Joe never let cancer take his hope. He firmly believed that Curebound-funded research gave him treatment options that gave him more time with his family. That belief is his legacy."
Registration is open now for participants to ride, run, walk, spin, flow, volunteer, or donate. The 2026 Cancer Challenge sponsors include UC San Diego, Janux Therapeutics, Genentech (Poseida Therapeutics), RayzeBio, Pfizer, Eisai, Illumina, ResMed, Vividion Therapeutics, JP Morgan, Dexcom, and numerous other regional and national organizations.